Genotypic Frequencies of Mutations Associated with Alpha-1 Antitrypsin Deficiency in Unrelated Bone Marrow Donors from the Murcia Region Donor Registry in the Southeast of Spain.
AAT1 deficiency
Pi system
SERPINE1 gene
chronic obstructive pulmonary disease
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
02 Sep 2023
02 Sep 2023
Historique:
received:
27
07
2023
revised:
27
08
2023
accepted:
30
08
2023
medline:
9
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
Alpha-1 antitrypsin (AAT1) deficiency (AAT1D) is an inherited disease with an increased risk of chronic obstructive pulmonary disease (COPD), liver disease, and skin and blood vessel problems. AAT1D is caused by mutations in the SERPINE1 gene (Serine Protease Inhibitor, group A, member 1). Numerous variants of this gene, the Pi system, have been identified. The most frequent allelic variants are Pi*M, Pi*S, and Pi*Z. The development of COPD requires both a genetic predisposition and the contribution of an environmental factor, smoking being the most important. Studies on this deficiency worldwide are very scarce, and it is currently considered a rare disease because it is underdiagnosed. The aim of this study was to analyze the genotypic frequencies of mutations associated with AAT1 deficiency in unrelated bone marrow donors from the donor registry of the Region of Murcia in southeastern Spain due to the high risk of presenting with different pathologies and underdiagnosis in the population. A total of 112 DNA-healthy voluntary unrelated bone marrow donors from different parts of the Region of Murcia were analyzed retrospectively. AAT1 deficiency patient testing involved an automated biochemical screening routine. The three main variants, Pi*M, Pi*Z, and Pi*S, were analyzed in the SERPINE1 gene. Our results showed a frequency of 3.12% of the Pi*Z (K342) mutation in over 224 alleles tested in the healthy population. The frequency of Pi*S (V264) was 11.1%. The frequency of the haplotype with the most dangerous mutation, EK342 EE264, was 4.46%, and the frequency of EK342 EV264 was 1.78% in the healthy population. Frequencies of other EE342 EV264-mutated haplotypes accounted for 18.7%. As for the EE342 VV264 haplotype, 0.89% of the total healthy population presented heterozygous for the EV264 mutation and one individual presented homozygous for the VV264 mutation. In conclusion, the frequencies of Pi mutations in the healthy population of the Region of Murcia were not remarkably different from the few studies reported in Spain. The genotype and haplotype frequencies followed the usual pattern. Health authorities should be aware of this high prevalence of the Pi*S allelic variant and pathological genotypes such as Pi*MZ and Pi*SZ in the healthy population if they consider screening the smoking population.
Identifiants
pubmed: 37685383
pii: diagnostics13172845
doi: 10.3390/diagnostics13172845
pmc: PMC10486455
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III (ISCIII)
ID : P19/01194
Organisme : European Union with the European Fund of Regional Development (FEDER)
ID : "A manner to build Europe."
Références
Arch Bronconeumol. 2006 Dec;42(12):645-59
pubmed: 17178069
Int J Mol Sci. 2021 May 29;22(11):
pubmed: 34072295
Environ Health Perspect. 2003 Dec;111(16):1851-4
pubmed: 14654440
Eur Respir J. 2006 Dec;28(6):1091-9
pubmed: 17005586
Clin Chim Acta. 1967 May;16(2):199-203
pubmed: 4166396
Eur Respir J. 2017 Nov 30;50(5):
pubmed: 29191952
Lancet. 2022 Sep 17;400(10356):921-972
pubmed: 36075255
Am J Respir Cell Mol Biol. 2003 Jul;29(1):57-61
pubmed: 12600819
Eur Respir J. 2010 May;35(5):960-8
pubmed: 20436173
Arch Bronconeumol. 2006 Jun;42(6):290-8
pubmed: 16827978
Thorax. 2007 Sep;62(9):806-13
pubmed: 17389752
Vox Sang. 1968;15(5):396-400
pubmed: 5699691
Biochemistry. 1998 Aug 11;37(32):11239-45
pubmed: 9698370
Ther Adv Respir Dis. 2008 Feb;2(1):13-21
pubmed: 19124355
Hum Immunol. 2001 Sep;62(9):910-21
pubmed: 11543893
J Parasitol. 1997 Aug;83(4):771-4
pubmed: 9267429
Am J Hum Genet. 1978 Nov;30(6):660-2
pubmed: 311585
Am J Respir Crit Care Med. 2003 Oct 1;168(7):818-900
pubmed: 14522813
PLoS Genet. 2009 Mar;5(3):e1000421
pubmed: 19300482
J Biol Chem. 1989 Jun 25;264(18):10477-86
pubmed: 2567291
FEBS Lett. 1992 Mar 23;300(1):21-4
pubmed: 1312485
Nat Rev Dis Primers. 2016 Jul 28;2:16051
pubmed: 27465791
Lancet. 1985 Jan 19;1(8421):152-4
pubmed: 2857224
J Intern Med. 2014 Oct;276(4):311-35
pubmed: 24661570
N Engl J Med. 2002 Jan 3;346(1):45-53
pubmed: 11778003
Proc Am Thorac Soc. 2006 Jul;3(5):424-7
pubmed: 16799086
Expert Opin Ther Targets. 2018 Aug;22(8):687-701
pubmed: 30028216
Mutat Res Rev Mutat Res. 2017 Jul;773:14-25
pubmed: 28927525
Clin Exp Immunol. 2021 Feb;203(2):315-328
pubmed: 33025622
J Clin Invest. 1987 Nov;80(5):1289-95
pubmed: 2824559
J Clin Invest. 1987 Nov;80(5):1366-74
pubmed: 3500183
Respir Med. 2011 Aug;105(8):1129-39
pubmed: 21367592
Ann Hematol. 2007 Jun;86(6):455-7
pubmed: 17235517
COPD. 2005 Jun;2(2):263-75
pubmed: 17136953
Thorax. 2004 Mar;59(3):259-64
pubmed: 14985567
Am J Physiol Lung Cell Mol Physiol. 2015 Jan 15;308(2):L179-90
pubmed: 25416382